These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25425972)

  • 1. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
    Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
    Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy.
    Abdel-Fatah TM; Albarakati N; Bowell L; Agarwal D; Moseley P; Hawkes C; Ball G; Chan S; Ellis IO; Madhusudan S
    Breast Cancer Res Treat; 2013 Dec; 142(3):515-27. PubMed ID: 24253812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer.
    Abdel-Fatah TM; Perry C; Moseley P; Johnson K; Arora A; Chan S; Ellis IO; Madhusudan S
    Breast Cancer Res Treat; 2014 Feb; 143(3):411-21. PubMed ID: 24381055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin.
    Lv J; Qian Y; Ni X; Xu X; Dong X
    Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
    Abdel-Fatah TM; Perry C; Arora A; Thompson N; Doherty R; Moseley PM; Green AR; Chan SY; Ellis IO; Madhusudan S
    Antioxid Redox Signal; 2014 Dec; 21(16):2262-8. PubMed ID: 25111287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Colleoni M; Cole BF; Viale G; Regan MM; Price KN; Maiorano E; Mastropasqua MG; Crivellari D; Gelber RD; Goldhirsch A; Coates AS; Gusterson BA
    J Clin Oncol; 2010 Jun; 28(18):2966-73. PubMed ID: 20458051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
    Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
    Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
    Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
    Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
    Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
    Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
    Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.